Antitumor activities of EGFR/HER2/HER4 kinase inhibitor S-222611 in the experimental brain metastases of HER2-positive breast cancer

被引：0
|
作者：
Hirata, Michinari
Tanaka, Yukari
Shinonome, Satomi
Yamada, Tomomi
Torii, Mikinori
Nezasa, Kenichi
Tanaka, Hidekazu
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-4073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4073
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib
    Tomasello, Gianluca
    Bedard, Philippe L.
    de Azambuja, Evandro
    Lossignol, Dominique
    Devriendt, Daniel
    Piccart-Gebhart, Martine J.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2010, 75 (02) : 110 - 121
  • [42] Appearance and therapy of brain metastases in patients with HER2-positive breast cancer
    Witzel, I
    Hemminger, G.
    Ihnen, M.
    Jaenicke, F.
    Mueller, V
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S137 - S137
  • [43] Prevention strategies for brain metastases from HER2-positive breast cancer
    Le Tourneau, Christophe
    BULLETIN DU CANCER, 2011, 98 (04) : 445 - 449
  • [44] HER2-positive breast cancer
    Loibl, Sibylle
    Gianni, Luca
    LANCET, 2017, 389 (10087): : 2415 - 2429
  • [45] Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
    Wei, Ruicheng
    Zhang, Wenli
    Yang, Futang
    Li, Qianhao
    Wang, Qingyu
    Liu, Ningshu
    Zhu, Jun
    Shan, Yongqiang
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [46] A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Zhang, Pin
    Wang, Lin
    Zhen, Yueying
    Wang, Zhihong
    Zhang, Hesheng
    Jones, Richard
    Xu, Binghe
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
  • [47] Efficacy of HER2 ADCs against HER2 inhibitor resistance alterations in the PI3K and MAPK pathways in HER2-positive breast cancer
    Ferraro, Emanuela
    Safonov, Anton
    Chen, Yuan
    White, Charlie
    Marra, Antonio
    Ahmed, Mehnaj
    Acevedo, Barbara
    Dang, Chau T.
    Modi, Shanu
    Solit, David B.
    Norton, Larry
    Robson, Mark E.
    Reis-Filho, Jorge
    Chandarlapaty, Sarat
    Razavi, Pedram
    CANCER RESEARCH, 2023, 83 (05)
  • [48] Cytoplasmic and Nuclear HER4 Expression in HER2 Negative Breast Cancer Cell Lines
    Nafi, Siti Norasikin Mohd
    Ali, Nursyazana Aqilah
    SAINS MALAYSIANA, 2022, 51 (03): : 859 - 864
  • [49] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Akio Kaito
    Takeshi Kuwata
    Masanori Tokunaga
    Kohei Shitara
    Reo Sato
    Tetsuo Akimoto
    Takahiro Kinoshita
    World Journal of Clinical Cases, 2019, (15) : 1964 - 1977
  • [50] HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
    Kaito, Akio
    Kuwata, Takeshi
    Tokunaga, Masanori
    Shitara, Kohei
    Sato, Reo
    Akimoto, Tetsuo
    Kinoshita, Takahiro
    WORLD JOURNAL OF CLINICAL CASES, 2019, 7 (15) : 1964 - 1977
12345